3.1 Inclusion Criteria 3.1.1. Histologically documented adenocarcinoma of the prostate. 3.1.2. Men at least 18 years of age and life expectancy of ≥ 6 months, ECOG performance status ≤ 2. 3.1.3 Metastatic disease as evidenced by soft tissue and/or bony metastases on baseline bone scan and/or computed tomography (CT) scan or MRI of the abdomen and pelvis. 3.1.4 Castration resistant prostatic adenocarcinoma. Subjects must have current or historical evidence of disease progression despite castrated level of testosterone (< 50 ng/dL) achieved by orchiectomy or LHRH agonist or antagonist therapy. Disease progression has to be demonstrated by PSA progression OR progression of measurable disease OR progression of non-measurable disease as defined below: 3.1.4.1 PSA: Two consecutive rising PSA values, at least 7 days apart. 3.1.4.2 Measurable disease: ≥ 20% increase in the sum of the longest diameters of all measurable lesions or the development of any new lesions. The change will be measured against the best response to castration therapy or against the pre-castration measurements if there was no response. 3.1.4.3 Non-measurable disease 3.1.4.3.1 Soft tissue disease: The appearance of 1 or more new lesions, and/or unequivocal worsening of non-measurable disease when compared to imaging studies acquired during castration therapy or against the pre-castration studies if there was no response. 3.1.4.3.2 Bone disease: Appearance of 2 or more new areas of abnormal uptake on bone scan when compared to imaging studies acquired during castration therapy or ag ainst the pre-castration studies if there was no response. Increased uptake of pre-existing lesions on bone scan does not constitute progression. 3.1.5 Following criteria are suggested guidelines and exceptions will be allowed at the discretion of Principal Investigator.